Dedicated to Improving Global Health.
Temptime Corporation is deeply committed to improving global public health. For nearly 30 years, our temperature monitoring devices have helped healthcare workers immunize millions of children around the world and extend care to regions previously thought to be unreachable.
Founded in 1987, Temptime scientists developed the first miniaturized technology to monitor temperature exposure of vials containing the oral polio vaccine. This time-temperature monitoring device continues to be the only technology that meets the strict specifications of the world’s leading health organization for distributing vaccines to developing countries. It satisfies the World Health Organization’s (WHO) PQS VVM performance specification, and we follow WHO’s guidelines for manufacturers of temperature monitoring devices.
Today, pharmaceutical corporations, biotechnology companies and hospitals are using our devices to help improve the storage and handling of hundreds of medical products by visually identifying when a temperature excursion has occurred. We are honored to serve these organizations and contribute to improving the health of people around the world. Temptime is dedicated to continually developing new technologies that will meaningfully improve global health for years to come.
Temptime’s leaders uphold the utmost integrity and work tirelessly as a network, unified in the desire to promote and improve global public health and better patient outcomes.
Renaat Van den Hooff
CEO, President and Member of the Board of Directors
Renaat Van den Hooff is CEO, president and a member of the Board of Directors of Temptime Corporation. Before joining Temptime, Renaat was the president and CEO of a public startup healthcare company that developed and sold innovative wound care products. Previously, Renaat had a 20-year career with Johnson & Johnson, where he served as the worldwide president of the J&J-Merck consumer pharmaceuticals joint venture. During his career at J&J, Renaat served in numerous positions of increasing responsibility in Belgium, England and the United States. Renaat earned a master’s degree in Marketing from the Vlerick Leuven-Gent Management School. He serves on the Board of Trustees of the National Multiple Sclerosis Foundation (Greater Delaware Valley Chapter).
Chief Financial Officer
Nick Hart is responsible for Finance and Information Systems. Nick has worked in the Life Sciences sector for over thirty years with extensive international experience in licensing, M&A and fundraising, both public and private. Prior to joining the Temptime team in 2014, Nick served as Acting President and CFO of HemCon Medical Technologies, Inc. He received his bachelor’s degree in economics and statistics from Kingston University, London and is a fellow member of the Institute of Chartered Management Accountants.
Dr. Ted Prusik
Senior Vice President
Dr. Ted Prusik is the Senior Vice President and is one of the co-founders of the company. Ted joined E.R. Squibb and Sons as research investigator in physical chemistry in 1977 and then moved to Allied Corporation in 1981. He worked as the Manager of Materials Development in the Specialty Polymers Group investigating the use of chromatic materials as environmental sensors to meet the needs of the food and pharmaceuticals industry. In 1987, the group was spun off as an independent company which became Temptime Corporation. Ted has 21 US patents issued and 14 patents pending and is a co-inventor of the HEATmarker VVM. Ted Prusik received his BS degree in Chemistry from Bucknell University and his MS and PhD degrees in Chemical Physics from New York University.
Vice President Global Customer Development
Chris Caulfield is the Vice President of Global Customer Development at Temptime Corporation. He has an international role and is responsible for developing the company’s strategy for customer development, key account management and growth, and new market identification and development. Chris joined Temptime Corporation in 2000 and has held positions of ever expanding authority and decision making within the company. He works directly with Temptime’s global pharmaceutical and vaccine manufacturing customers, global health agencies, and ministries of health. Chris has a domestic USA based sales team as well as business development representatives in China, India, Russia, Japan, Turkey, and the Middle East. He earned a B.A in Economics, as well as a minor in political science, from Villanova University (Villanova, PA).
Vice President Quality, R&D and Regulatory Affairs
Steve Feldman is the Vice President of Quality, R&D, and Regulatory Affairs at Temptime Corporation. Previously, he held the positions of Quality Assurance Director at Boston Scientific Corporation and Director of Quality Assurance at Johnson & Johnson, before joining the Temptime team in 2004. Steve has a Master’s of Science Degree in Engineering Management from California State University-Northridge and a Bachelor’s of Science in Chemical Engineering from Cal Poly Pomona.
Vice President Operations
Brad Mataczynski is the Vice President of Operations at Temptime Corporation. Brad is responsible for manufacturing operations, engineering, facilities and business continuity planning. Before joining Temptime in 2002 Brad held various leadership roles of increasing responsibility at International Paper and Brady Corporation. Brad has a Master’s Degree in Business Administration from Marquette University and a Bachelor’s of Science Degree in Mechanical Engineering from the University of Wisconsin-Madison.
Executive Director, Global Health Policy
Michael Rush is the Executive Director of Global Health Policy, responsible for advocacy and implementation of domestic and international health policies incorporating temperature monitors to improve patient outcomes, public health, product integrity, and supply chain cost-efficiencies. Mike works in collaboration with government officials, NGOs, agency leaders, and global health policymakers from organizations such as WHO, UNICEF, Gavi, the Gates Foundation, and PATH. Previously, Mike worked for 13 years at Merck Vaccines, taking on roles of increasing responsibility for all facets of vaccine public sector access, funding, and policy in the Americas, collaborating with such organizations as the U.S. CDC, the Pan American Health Organization, and governments in Latin America and the Caribbean. Mike has lived and worked in Perú, Spain, and Brazil and fluently speaks Spanish and Portuguese. He has a Master’s Degree in International Business Administration from Northwest Nazarene University and a Bachelor’s Degree in Industrial Psychology from Weber State University.
Sr. Director of Finance
Bill Smiley is the Director of Finance at Temptime Corporation. He leads accounting, finance and payroll functions at Temptime and has been a part of the Temptime team since 1999. Previously, Bill acted as Director of Finance at Monroe County Transportation Authority. Expertise includes financial reporting, budgeting/planning, financial analysis and cash management. He has a Bachelor’s Degree in Accounting from Fort Lauderdale College.
Executive Director, Human Resources
Becky is an accomplished human resources professional with an extensive and proven track record of partnering with business leaders, in a variety of industries to build winning cultures, leadership at all levels, and practices that drive performance and business results. Becky’s focus is to partner with Temptime leaders to continue advancing performance and profitability by aligning the HR strategy, system and programs with Temptime’s business objectives. Becky’s HR work ranges from start-ups to established organizations, with experience in creating HR strategy, program design and implementation, employee relations, talent management and talent selection and retention. Prior to joining Temptime, Becky most recently held the position of executive director of human resources with Shire Pharmaceuticals. Becky holds a B.S. in Hotel & Restaurant Administration and a minor in business from the University of New Haven (CT).
SCIENTIFIC ADVISORY BOARD
The Temptime Scientific Advisory Board (SAB) provides strategic guidance and direction to our research and scientific programs, fostering and prioritizing creative ideas and strategies for novel products and services that improve the user experience while delivering exceptional value.
These innovations would be provided to our clients across the globe in the form of new technologies and significant enhancements that more fully leverage our existing platforms. The goal for developing all of our future products and services would be to extend and expand upon the breadth and depth of Temptime’s scientific advancements so as to significantly contribute to our vision of elevating the quality of global health.
John Irvin, BS, MD, PhD
Chairman of the Scientific Advisory Board
Chairman of the Scientific Advisory Board; expert in drug development, medical and regulatory affairs; former industry senior executive.
Ron Chance, PhD
Executive Vice President and Head of Engineering for Algenol Biotech; Adjunct Professor in the School of Biomolecular and Chemical Engineering, Georgia Tech; one of the early pioneers in diacetylene solid state reaction kinetics and optical properties of polydiacetylenes. Current work focused on CO2 capture and utilization in algal biofuels.
Managing Partner and Principal Consultant, Blue Fin Group, Naples, FL; expert in Global Supply Chain issues, including cold chain; former industry senior executive.
Sanjay Sarma, PhD
Professor of Mechanical Engineering and Director of Digital Learning, Massachusetts Institute of Technology (MIT), Boston, MA; expert in new supply chain technologies including RFID.
David Volkin, PhD
Pharmaceutical Chemistry Professor, School of Pharmacy, University of Kansas, Lawrence, KS; academic and industry experience with heat/freeze sensitive healthcare products.
Corey Casper, MD, MPH
Head, Program in Global Oncology and Full Member, Vaccine and Infectious Disease and Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center; Professor, Allergy & Infectious Diseases Division and Professor, Epidemiology and Global Health, University of Washington; expert in infection-related cancers, cancer in low-resource settings, use of biologics for the treatment of infectious diseases and cancer, design and conduct of clinical trials, and vaccine development.